By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics startup Xagenic today announced the closing of a Series A financing round that raised C$10 million (US$10 million).

CTI Life Sciences Fund and the Ontario Emerging Technologies Fund led the round, with "significant participation" by Qiagen, Toronto-based Xagenic said. The money will go toward the development of a decentralized molecular diagnostic platform for use in doctors' offices, clinics, and hospital systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.